FDA Approves Pfizer's Extended Release Xeljanz for Ulcerative Colitis

Pfizer’s Xeljanz (tofacitinib) won approval from the U.S. Food and Drug Administration (FDA) as a treatment for patients with moderately to severely active ulcerative colitis (UC), after an inadequate response or intolerance to tumor necrosis factor inhibitor (TNFi) blockers.